Biocon peers

·Pharma & HealthChart ›

Companies like Bioconlatest year

BioconBIOCON · FY26 · this company
Market cap₹56,848
P/E124.36×
Sales growth+10.0%
ROE1.4%
Sun Pharmaceutical IndustriesSUNPHARMA · FY26
Open ›
Market cap₹4,21,677
P/E36.77×
Sales growth+10.5%
ROE14.7%
Dr. Reddy's LaboratoriesDRREDDY · FY26
Open ›
Market cap₹1,11,506
P/E26.49×
Sales growth−1.5%
ROE11.8%
Syngene InternationalSYNGENE · FY26
Open ›
Market cap₹16,553
P/E52.20×
Sales growth−8.6%
ROE6.6%

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BIOCON₹350.70

Biocon Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYSYNGENEMANKINDGLENMARKLAURUSLABSALKEMLUPINMcap ₹56,848 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
BIOCON
FY26
SUNPHARMA
FY26
DRREDDY
FY26
SYNGENE
FY26
Peer
Average
Valuation — at last close
P/E124.36×36.77×◆ 26.49×52.20×38.49× +223%
P/B◆ 1.67×5.05×2.94×3.42×3.80× -56%
EV/EBITDA20.37×22.19×17.19×◆ 16.63×18.67× +9%
Market Cap₹56,848 Cr₹4.22L Cr₹1.12L Cr₹16,553 Cr₹1.83L Cr -69%
Growth
Revenue CAGR 3Y◆ 14.85%10.03%10.96%5.40%8.80% +69%
Revenue CAGR 5Y◆ 18.96%11.78%12.09%11.35%11.74% +61%
Net Income CAGR 3Y-16.91%◆ 10.57%-2.66%-11.98%-1.36% -1146%
Revenue YoY (latest Q)10.00%◆ 10.46%-1.48%-8.55%0.14% +6877%
Net Income YoY (latest Q)◆ 53.36%26.53%-31.69%-52.01%-19.06% +380%
Profitability
EBITDA Margin20.41%◆ 30.33%19.15%24.57%24.68% -17%
Net Income Margin2.18%◆ 19.69%12.34%8.47%13.50% -84%
Return on Common Equity1.39%◆ 14.74%11.75%6.62%11.04% -87%
Return on Capital Employed3.19%◆ 18.48%11.30%8.54%12.77% -75%
Return on Assets0.60%◆ 11.46%7.73%4.57%7.92% -92%
Credit & Quality
Total Debt/Equity0.40×0.05×0.16×◆ 0.00×0.07× +471%
Interest Coverage1.51×◆ 43.65×11.76×9.54×21.65× -93%
Scale — latest FY
Revenue / Total Income₹16,927 Cr₹58,462 Cr₹33,700 Cr₹3,739 Cr₹31,967 Cr -47%
Net Income₹369 Cr₹11,509 Cr₹4,158 Cr₹317 Cr₹5,328 Cr -93%
Total Assets₹63,651 Cr₹1.09L Cr₹58,123 Cr₹7,055 Cr₹57,988 Cr +10%
EPS₹2.82₹47.8₹50.41₹7.87₹35.36 -92%
Book Value per Share₹209.94₹348.31₹453.79₹120.11₹307.4 -32%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.